About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5320791
Allelic
Composition
Jak2tm1Mohi/Jak2tm1Mohi
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Jak2tm1Mohi mutation (0 available); any Jak2 mutation (5 available)
Tg(Mx1-cre)1Cgn mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• increased Gr-1/Mac-1+ cells in the spleen of pIpC-treated mice (J:183821)
• increased Gr-1/Mac-1+ cells in the spleen of pIpC-treated mice (J:183821)
• increased myeloid, megakaryocyte/erythroid and granulocyte/macrophage progenitors in the bone marrow and spleen of pIpC-treated mice (J:183821)
• increased granulocyte-macrophage progenitors in the spleen of pIpC-treated mice (J:183821)
• increased myeloid, megakaryocyte/erythroid and granulocyte/macrophage progenitors in the bone marrow and spleen of pIpC-treated mice (J:183821)
• increased granulocyte-macrophage progenitors in the spleen of pIpC-treated mice (J:183821)
• increased myeloid progenitors in the spleen of pIpC-treated mice (J:183821)
• increased myeloid progenitors in the spleen of pIpC-treated mice (J:183821)
• in pIpC-treated mice with trilineage hyperplasia (J:183821)
• in pIpC-treated mice with trilineage hyperplasia (J:183821)
• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors (J:183821)
• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors (J:183821)
• in the splenic red pulp of pIpC-treated mice (J:183821)
• 20-fold increase in CD71/Ter-119+ cells in the spleen of pIpC-treated mice (J:183821)
• in the bone marrow and spleen of pIpC-treated mice (J:183821)
• in the splenic red pulp of pIpC-treated mice (J:183821)
• 20-fold increase in CD71/Ter-119+ cells in the spleen of pIpC-treated mice (J:183821)
• in the bone marrow and spleen of pIpC-treated mice (J:183821)
• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks (J:183821)
• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks (J:183821)
• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks (J:183821)
• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks (J:183821)
• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in the bone marrow and spleen of pIpC-treated mice (J:183821)
• in the bone marrow and spleen of pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in the bone marrow and spleen of pIpC-treated mice (J:183821)
• in the bone marrow and spleen of pIpC-treated mice (J:183821)
• reticulin fibrosis in pIpC-treated mice (J:183821)
• reticulin fibrosis in pIpC-treated mice (J:183821)
• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors (J:183821)
• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• fibrosis in pIpC-treated mice (J:183821)
• fibrosis in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• fibrosis in the splenic red and white pulp of pIpC-treated mice (J:183821)
• fibrosis in the splenic red and white pulp of pIpC-treated mice (J:183821)

immune system
• increased Gr-1/Mac-1+ cells in the spleen of pIpC-treated mice (J:183821)
• increased Gr-1/Mac-1+ cells in the spleen of pIpC-treated mice (J:183821)
• in the bone marrow and spleen of pIpC-treated mice (J:183821)
• in the bone marrow and spleen of pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• reticulin fibrosis in pIpC-treated mice (J:183821)
• reticulin fibrosis in pIpC-treated mice (J:183821)
• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors (J:183821)
• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• fibrosis in pIpC-treated mice (J:183821)
• fibrosis in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• in pIpC-treated mice (J:183821)
• fibrosis in the splenic red and white pulp of pIpC-treated mice (J:183821)
• fibrosis in the splenic red and white pulp of pIpC-treated mice (J:183821)

skeleton
• fibrosis in pIpC-treated mice (J:183821)
• fibrosis in pIpC-treated mice (J:183821)
• fibrosis in the bone marrow cavity of pIpC-treated mice (J:183821)
• fibrosis in the bone marrow cavity of pIpC-treated mice (J:183821)

Mouse Models of Human Disease
OMIM ID Ref(s)
Polycythemia Vera; PV 263300 J:183821


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory